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I.	  Introduction	  	  
	   Recent	  estimates	  suggest	  that	  two	  million	  people	  in	  the	  United	  States	  are	  currently	  dependent	  on	  opioid	  drugs.1	  In	  2010,	  the	  Global	  Burden	  of	  Disease	  Study	  reported	  that	  approximately	  15.5	  million	  opioid	  dependent	  individuals	  exist	  globally,	  and	  that	  the	  estimated	  morbidity	  caused	  by	  opioid	  dependence	  had	  increased	  by	  nearly	  75%	  from	  the	  prior	  study	  in	  1990.2	  Opioid	  overdose	  is	  now	  the	  second	  most	  common	  cause	  of	  accidental	  death	  in	  the	  United	  States,	  and	  opioid	  addiction	  is	  the	  cause	  of	  well-­‐documented	  increases	  in	  the	  risks	  of	  depression,	  suicide,	  HIV	  and	  Hepatitis	  C.3	  With	  respect	  to	  the	  financial	  burden	  of	  disease,	  in	  2001	  the	  total	  cost	  of	  prescription	  opioid	  misuse	  alone	  was	  greater	  than	  8	  billion	  dollars;	  earlier	  studies	  have	  estimated	  that	  annual	  direct	  health	  care	  costs	  for	  opioid	  users	  average	  nearly	  9x	  higher	  than	  non-­‐opioid	  users.4	  Despite	  this,	  fewer	  than	  10%	  of	  people	  who	  struggle	  with	  addiction	  receive	  appropriate	  pharmacologic	  therapy.5	  	  Buprenorphine	  is	  a	  partial	  mu-­‐opioid	  receptor	  agonist	  that	  was	  approved	  by	  the	  FDA	  in	  2002	  for	  use	  in	  treating	  opioid	  addiction.6	  The	  number	  of	  prescriptions	  for	  buprenorphine	  formulations	  has	  nearly	  doubled	  every	  year	  since,	  with	  an	  estimated	  6	  million	  prescriptions	  written	  in	  2009.7	  This	  trend	  has	  been	  bolstered	  by	  numerous	  randomized	  controlled	  trials	  showing	  that	  buprenorphine	  can	  perform	  as	  well	  as	  methadone	  in	  reducing	  illicit	  opioid	  use	  among	  patients	  with	  opioid	  addiction.8	  Documented	  advantages	  of	  buprenorphine	  treatment	  over	  methadone	  include	  lower	  risk	  of	  toxicity/overdose,	  access	  at	  office-­‐based	  practices,	  lower	  abuse	  potential,	  milder	  withdrawal	  symptoms,	  and	  ability	  to	  self-­‐administer	  medications	  at	  home.9	  	  Understanding	  the	  potential	  for	  medical	  therapies	  in	  this	  realm	  is	  a	  pressing	  need.	  In	  response	  to	  the	  widespread	  problem	  of	  drug	  addiction,	  the	  Affordable	  Care	  Act	  named	  ‘Substance	  Use	  Disorders’	  one	  of	  the	  10	  elements	  of	  its	  Essential	  Health	  Benefits,	  requiring	  all	  health	  insurance	  policies	  purchased	  on	  insurance	  exchanges	  to	  fully	  cover	  treatment	  and	  support	  for	  substance	  use	  disorders.10	  Parallel	  increases	  in	  the	  rates	  of	  opioid	  addiction,	  physician	  comfort	  with	  using	  buprenorphine,	  and	  access	  to	  addiction	  treatment	  can	  be	  expected	  to	  increase	  the	  demand	  for	  quality,	  evidence-­‐based	  addiction	  therapy.	  Despite	  the	  growing	  use	  of	  buprenorphine	  and	  the	  burden	  of	  opioid	  addiction,	  only	  a	  small	  number	  of	  studies	  have	  investigated	  which	  factors	  influence	  success	  or	  failure	  of	  opioid	  replacement	  therapy,	  especially	  when	  treatment	  is	  initiated	  in	  the	  primary	  care	  setting.	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   This	  project	  aims	  to	  build	  upon	  prior	  work	  and	  pave	  the	  way	  for	  objective	  tools	  that	  physicians	  can	  use	  to	  analyze	  a	  given	  patient’s	  prognosis	  for	  addiction	  treatment	  with	  buprenorphine.	  By	  investigating	  easily	  observable,	  definable	  patient	  characteristics	  and	  creating	  models	  that	  predict	  patient	  outcome,	  we	  hope	  not	  only	  to	  uncover	  the	  psychosocial	  determinants	  of	  treatment	  response,	  but	  to	  identify	  ways	  in	  which	  physicians	  can	  risk-­‐stratify	  patients	  who	  are	  interested	  in	  buprenorphine	  therapy,	  and	  allocate	  their	  support	  resources	  accordingly.	  	  	   A	  number	  of	  prior	  studies	  have	  pursued	  answers	  to	  similar,	  related	  questions,	  which	  helped	  to	  shed	  light	  on	  the	  variables	  we	  chose	  to	  investigate.	  For	  example,	  a	  2007	  study	  which	  investigated	  an	  overlapping	  population	  followed	  a	  cohort	  of	  99	  patients	  who	  were	  on	  a	  buprenorphine	  care	  protocol	  at	  one	  of	  two	  primary	  care	  clinics,	  and	  looked	  for	  predictive	  correlates	  of	  physician-­‐judged	  sobriety	  at	  the	  end	  of	  6	  months,	  finding	  that	  private	  insurance,	  older	  age,	  and	  attendance	  at	  self-­‐help	  meetings	  correlated	  with	  treatment	  success.11	  By	  documenting	  a	  ‘success	  rate’	  of	  54%,	  they	  concluded	  that	  outpatient	  buprenorphine	  treatment	  in	  a	  primary	  care	  setting	  is	  a	  viable	  model	  for	  addiction	  care	  delivery.	  Another	  study,	  focusing	  exclusively	  on	  prescription	  opioid	  use	  also	  found	  increased	  age	  to	  correlate	  with	  success	  at	  12	  weeks,	  but	  also	  found	  relationships	  between	  success	  and	  a	  diagnosis	  of	  depression,	  first	  time	  treatment,	  and	  negative	  history	  of	  injection	  drug	  use.12	  Studies	  using	  even	  shorter	  follow	  up	  periods	  of	  4	  weeks	  found	  age,	  lack	  of	  criminal	  history,	  and	  decreased	  frequency/dose	  of	  opioid	  use	  to	  be	  correlated	  with	  sobriety.13	  Finally,	  one	  of	  the	  largest	  analyses	  of	  this	  type	  examined	  382	  patients	  with	  a	  one	  year	  follow	  up	  period;	  again,	  older	  patients	  fared	  better,	  in	  addition	  to	  patients	  who	  were	  employed,	  and	  interestingly,	  those	  who	  had	  used	  buprenorphine	  which	  they	  had	  purchased	  on	  the	  street.14	  Building	  upon	  this	  foundation,	  we	  performed	  a	  retrospective	  cohort	  analysis	  on	  10	  years	  of	  data	  from	  160	  patients	  who	  received	  buprenorphine	  therapy	  for	  opioid	  addiction	  at	  a	  community	  health	  center	  in	  Boston.	  Data	  were	  collected	  via	  intensive	  chart	  review	  on	  36	  demographic,	  psychosocial,	  and	  medical	  variables.	  Patients	  were	  followed	  for	  1	  year	  after	  initiating	  buprenorphine	  therapy,	  and	  were	  assigned	  to	  outcome	  groups	  based	  on	  objective	  toxicology	  screens.	  Finally,	  two	  levels	  of	  statistical	  analysis	  were	  performed	  to	  uncover	  both	  unadjusted,	  and	  adjusted	  logistic	  predictors	  of	  treatment	  success	  and	  failure.	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This	  study	  offers	  several	  qualities	  that	  distinguish	  it	  from	  the	  majority	  of	  prior	  work	  on	  the	  topic.	  First,	  it	  has	  the	  benefit	  of	  a	  longer,	  longitudinal	  follow-­‐up	  period	  than	  most	  pre-­‐existing	  studies.	  While	  no	  consensus	  exists	  as	  to	  what	  constitutes	  absolute	  ‘treatment	  success,’	  a	  number	  of	  comparable	  studies	  have	  used	  single	  drug	  tests	  at	  4	  or	  12	  weeks	  as	  a	  proxy	  for	  sobriety.12,13	  Our	  approach	  can	  be	  expected	  to	  better	  capture	  the	  nature	  of	  addiction	  as	  a	  chronic	  disease,	  and	  account	  for	  the	  commonly	  occurring	  relapses	  or	  losses	  to	  follow-­‐up	  that	  may	  occur	  well	  into	  the	  course	  of	  treatment.	  Next,	  to	  our	  knowledge,	  no	  prior	  studies	  have	  used	  a	  three-­‐pronged	  approach	  to	  defining	  patient	  outcome	  (described	  in	  detail	  below).	  We	  believe	  that	  outcome	  categories	  of	  ‘Early	  Failure,’	  ‘Late	  Failure,’	  and	  ‘Long-­‐term	  Success’	  better	  reflect	  clinical	  realities,	  and	  exceed	  the	  ability	  of	  traditional	  dichotomous	  success/failure	  groupings	  to	  capture	  the	  true	  heterogeneity	  that	  exists	  in	  treatment	  responses.	  Finally,	  recent	  studies	  have	  uncovered	  the	  changing	  demographics	  of	  patients	  who	  are	  suffering	  from	  opioid	  addiction.	  What	  was	  once	  an	  inner-­‐city	  issue	  affecting	  mostly	  minorities	  now	  predominantly	  affects	  young	  whites	  who	  live	  in	  peri-­‐urban	  regions.15	  Our	  study	  population	  perfectly	  mirrors	  the	  ‘new	  face’	  of	  opioid	  addiction,	  and	  is	  therefore	  of	  increased	  relevance	  to	  the	  problems	  that	  physicians	  will	  face	  in	  the	  coming	  years.	  	  With	  an	  increasing	  amount	  of	  addiction	  occurring	  in	  such	  peri-­‐urban	  areas,	  the	  demand	  for	  outpatient	  primary	  care	  based	  addiction	  treatment	  will	  increase.	  For	  this	  reason,	  deriving	  the	  best	  ways	  to	  provide	  addiction	  care	  is	  increasingly	  relevant.	  To	  this	  end,	  this	  study	  attempts	  to	  answer	  the	  following	  questions:	  	  	  1)	  Which	  patients	  with	  opioid	  addiction	  can	  be	  expected	  to	  achieve	  long-­‐term	  success	  with	  buprenorphine	  therapy?	  	  2)	  Which	  patients	  are	  expected	  to	  fail	  treatment	  at	  the	  outset,	  during	  the	  induction	  phase?	  	  3)	  Which	  patients	  have	  a	  high	  risk	  of	  relapse	  during	  the	  course	  of	  treatment?	  	  	  We	  hope	  that	  the	  answers	  to	  these	  questions	  can	  not	  only	  inform	  which	  patients	  would	  benefit	  from	  extra	  resources,	  but	  also	  generate	  implementable	  ideas	  about	  how	  best	  to	  support	  patients	  through	  their	  recovery	  from	  opioid	  addiction.	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II.	  Methods	  	  
Subject	  Selection	  	  
	   All	  patients	  considered	  for	  inclusion	  in	  this	  study	  were	  seen	  over	  the	  past	  10	  years	  at	  the	  MGH	  Charlestown	  HealthCare	  Center	  (MGH	  CHCC)	  for	  long-­‐term	  buprenorphine	  maintenance	  therapy	  for	  opioid	  addiction.	  Individual	  subjects	  were	  all	  selected	  using	  the	  Partners	  Research	  Patient	  Data	  Registry	  (RPDR)	  data	  query	  tool.16	  RPDR	  is	  a	  centralized	  clinical	  data	  source,	  which	  accesses	  and	  compiles	  patient	  data	  via	  a	  number	  of	  online	  platforms.	  The	  program	  was	  asked	  to	  pull	  the	  names	  of	  patients	  who	  met	  two	  overlapping	  basic	  criteria:	  1)	  Patients	  who	  have	  been	  seen	  for	  medical	  care	  at	  Charlestown	  HealthCare	  Center,	  and	  2)	  Patients	  who	  have	  received	  a	  prescription	  for	  a	  buprenorphine	  formulation.	  The	  program	  retrieved	  a	  total	  of	  380	  patients	  who	  were	  members	  of	  both	  groups,	  and	  a	  total	  of	  300	  patients	  were	  investigated	  at	  random	  from	  this	  cohort.	  	  After	  140	  were	  excluded,	  160	  subjects	  were	  included	  in	  the	  final	  study.	  Please	  see	  Table	  1	  for	  Exclusion	  Criteria.	  	  	  
Table	  1:	  EXCLUSION	  CRITERIA	  	  
• Patient	  received	  buprenorphine	  therapy	  from	  a	  provider	  outside	  MGH	  Charlestown	  
• Patient	  initiated	  buprenorphine	  therapy	  >10	  years	  ago	  
• Patient	  initiated	  buprenorphine	  therapy	  <1	  year	  ago	  (thus	  had	  insufficient	  time	  for	  follow-­‐up)	  
• Patient	  was	  prescribed	  buprenorphine	  for	  pain,	  without	  signs/symptoms	  of	  opioid	  addiction	  
• Patient	  was	  already	  stable	  on	  buprenorphine	  and	  was	  accepted	  as	  a	  care	  transfer	  	  
• Patient	  was	  prescribed	  buprenorphine	  merely	  as	  a	  temporary	  bridge	  to	  other	  therapy	  	  
• Patient’s	  medical	  record	  had	  insufficient	  documentation	  to	  determine	  above	  criteria	  	  
Treatment	  Protocols	  	   This	  retrospective	  study	  did	  not	  enforce	  treatment	  protocols;	  instead,	  all	  clinical	  decisions	  were	  dictated	  by	  each	  individual	  buprenorphine	  provider.	  Patients	  thus	  varied	  in	  their	  prescribed	  buprenorphine	  regimen,	  frequency	  of	  visits,	  participation	  in	  counseling,	  induction	  protocol,	  and	  threshold	  for	  continuation/discontinuation	  of	  therapy.	  Frequency	  of	  follow-­‐up	  visits	  also	  differed	  based	  on	  patient	  response	  to	  therapy,	  availability,	  and	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patient	  comfort,	  such	  that	  some	  patients	  were	  seen	  weekly,	  and	  others	  monthly	  or	  bimonthly.	  	  However,	  since	  the	  study	  was	  performed	  using	  only	  patients	  who	  were	  seen	  at	  one	  site,	  significant	  continuity	  exists	  concerning	  the	  general	  framework	  of	  intake	  and	  care.	  All	  participating	  physicians	  were	  certified	  in	  the	  appropriate	  provision	  of	  buprenorphine	  to	  patients	  with	  opioid	  addiction.	  All	  patients	  were	  either	  self-­‐referred,	  or	  referred	  by	  other	  practitioners	  in	  the	  area,	  and	  participated	  in	  treatment	  voluntarily.	  No	  outreach	  was	  undertaken.	  Since	  the	  buprenorphine	  practice	  at	  MGH	  CHCC	  is	  often	  saturated,	  many	  patients	  were	  placed	  on	  a	  wait-­‐list	  until	  spots	  became	  available	  for	  them	  to	  participate	  in	  treatment.	  All	  patients	  were	  seen	  initially	  by	  a	  physician	  for	  evaluation	  of	  candidacy	  in	  the	  buprenorphine	  program,	  and	  in	  almost	  all	  circumstances,	  this	  visit	  was	  supplemented	  by	  an	  additional	  intake	  visit	  with	  a	  social	  worker	  or	  psychologist,	  in	  which	  comprehensive	  drug	  use	  and	  social	  histories	  were	  obtained.	  	  If	  patients	  were	  deemed	  to	  be	  suitable	  candidates	  for	  therapy	  based	  on	  a	  stated	  commitment	  to	  attend	  appointments	  and	  maintain	  open	  communication	  with	  doctors,	  they	  presented	  to	  the	  clinic	  for	  buprenorphine	  induction.	  At	  that	  appointment,	  a	  drug	  screen	  was	  performed,	  and	  the	  patient	  received	  a	  prescription	  for	  a	  limited	  quantity	  of	  buprenorphine	  at	  a	  dose	  ranging	  from	  4-­‐16mg/day.	  Patients	  were	  instructed	  to	  return	  for	  a	  prescription	  refill	  and	  a	  repeat	  toxicology	  screen	  at	  the	  end	  of	  an	  allotted	  interval.	  At	  that	  appointment,	  results	  of	  any	  prior	  toxicology	  screens	  would	  be	  discussed,	  and	  plans	  for	  the	  best	  way	  to	  proceed	  with	  treatment	  would	  be	  discussed.	  All	  patients	  were	  seen	  on	  a	  regular	  basis	  and	  received	  toxicology	  screens	  for	  the	  duration	  of	  their	  care.	  All	  patients	  were	  also	  strongly	  encouraged	  to	  participate	  in	  dedicated	  drug	  counseling	  sessions;	  both	  one-­‐on-­‐one	  and	  group	  therapy	  options	  were	  available.	  	  	  
Data	  Collection	  	   Patients	  were	  identified	  using	  their	  7-­‐digit	  MGH	  medical	  record	  number	  (MRN),	  which	  was	  produced	  as	  part	  of	  the	  RPDR	  data	  query.	  	  All	  detailed	  health	  information	  was	  obtained	  using	  the	  Queriable	  Patient	  Inference	  Dossier	  (QPID).	  QPID	  is	  an	  online	  platform,	  which	  intelligently	  searches	  a	  patient’s	  electronic	  medical	  records	  and	  returns	  tailored,	  relevant	  results.	  It	  is	  unique	  in	  that	  it	  is	  able	  to	  search	  by	  ‘concept’	  or	  ‘topic’	  and	  retrieve	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broader	  results	  than	  simple	  verbatim	  matches	  between	  the	  query	  term	  and	  patient	  data.	  	  QPID	  draws	  upon	  all	  available	  electronic	  health	  information,	  from	  patient	  notes	  entered	  by	  physicians	  to	  laboratory	  results	  and	  up	  to	  date	  comprehensive	  demographic	  data.	  For	  each	  patient	  in	  the	  study,	  a	  specific	  QPID	  search	  algorithm	  was	  used	  to	  retrieve	  all	  data	  (see	  Table	  2	  for	  details).	  	  	   All	  data	  were	  collected	  solely	  by	  the	  author	  of	  this	  manuscript.	  The	  data	  were	  collected	  in	  two	  stages.	  First,	  all	  necessary	  information	  was	  obtained	  concerning	  patient	  demographics	  and	  predictive	  variables.	  At	  this	  time,	  the	  query	  was	  blind	  to	  information	  concerning	  patient	  outcome,	  in	  order	  to	  minimize	  bias.	  Once	  this	  phase	  was	  completed	  for	  all	  subjects,	  another	  phase	  was	  initiated	  in	  which	  data	  were	  collected	  purely	  on	  outcome	  variables,	  this	  time	  blinded	  to	  predictor	  variables	  for	  the	  same	  reason.	  Final	  data	  values	  for	  each	  variable	  were	  determined	  by	  a	  comprehensive	  integration	  of	  all	  available	  information	  from	  clinical	  and	  laboratory	  data,	  including	  systematic	  intake	  notes	  completed	  on	  most	  patients.	  	  	   All	  data	  were	  entered	  into	  REDcap,	  a	  secure	  web	  application	  for	  building	  and	  managing	  online	  data	  sets.17	  In	  this	  way,	  data	  were	  stored	  online	  in	  a	  non-­‐centralized,	  non-­‐traceable	  fashion.	  Before	  data	  collection	  began,	  the	  author	  of	  this	  manuscript	  designed	  a	  custom	  data	  collection	  tool	  with	  built-­‐in	  mechanisms	  to	  protect	  data	  accuracy	  and	  prevent	  errors.	  For	  example,	  possible	  ranges	  of	  numerical	  data	  were	  restricted,	  dates	  were	  specifically	  coded,	  missing/equivocal	  fields	  were	  made	  to	  trigger	  flags,	  and	  drop-­‐down	  menus	  were	  designed	  to	  accommodate	  categorical	  variables.	  Once	  data	  collection	  was	  complete,	  REDCap	  was	  used	  to	  compile	  and	  export	  all	  of	  the	  coded	  data	  into	  an	  Excel	  file,	  which	  was	  used	  for	  statistical	  analysis.	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Table	  2:	  VARIABLES:	  DEFINITIONS	  AND	  SEARCH	  STRATEGY	  
Predictive	  Variable	   Definition	   QPID	  Search	  Strategy	  	  
Age	   At	  time	  of	  induction	   ‘Demographics’	  	  
Sex	   Male	  or	  Female	   ‘Demographics’	  	  
Induction	  Date	   Date	  of	  1st	  prescription	  for	  buprenorphine	   ‘suboxone,’	  ‘buprenorphine,’	  
‘bup,’	  ‘induction’	  
Injection	  Drug	  Use	   Any	  history	  of	  injection	  opioid	  use	  	   ‘heroin,’	  ‘IV,’	  ‘intravenous,’	  
‘injection,’	  ‘IVDU’	  	  
Intranasal	  Drug	  Use	   History	  of	  sniffing,	  snorting	  crushed	  opioids.	  
Cocaine	  not	  included	  	  
‘intranasal,’	  ‘snort,’	  ‘nasal,’	  
‘sniff’	  
Years	  of	  Active	  Use	   Years	  since	  first	  opioid	  use,	  subtracting	  all	  
periods	  of	  abstinence	  	  
When	  exact	  value	  not	  
recorded,	  estimates	  were	  made	  
using	  all	  available	  information	  
Cocaine	  use	  	   Endorsed	  use	  within	  1	  week	  of	  induction	   ‘cocaine,’	  ‘coke,’	  ‘crack’	  	  
Alcohol	  use	  	   Endorsed	  use	  within	  1	  week	  of	  induction,	  
includes	  binge	  episodes	  or	  >2	  drinks/day	  
‘drinks,’	  ‘drinker,’	  ‘alcohol’	  
Cigarette	  use	   Active	  smoking	   ‘smoker,’	  ‘smokes,’	  ‘cigarettes,’	  
‘pack(s)’	  	  
Marijuana	  use	   Endorsed	  use	  within	  1	  week	  of	  induction	   ‘marijuana,’	  ‘mj,’	  ‘weed,’	  	  
Non-­‐prescription	  
Benzodiazepine	  use	  	  
Endorsed	  use	  within	  1	  week	  of	  induction	   ‘benzo,’	  ‘benzos,’	  ‘xanax’	  	  
Non-­‐prescription	  
Buprenorphine	  use	  	  
Endorsed	  use	  of	  non-­‐prescription	  





Prior	  official,	  physician	  supported	  attempt	  





Prior	  official,	  physician	  supported	  attempt	  
at	  methadone	  maintenance	  
‘methadone,’	  ‘mmt’	  	  
Prior	  Detox	  attempt	  	   Prior	  official	  attempt	  at	  inpatient	  or	  
intensive	  outpatient	  detoxification	  	  
‘detox’	  	  
History	  of	  Overdose	  	   Verbal	  endorsement	  or	  EMR	  evidence	  of	  
least	  1	  prior	  drug	  overdose	  	  
‘od,’	  ‘overdose’	  	  
Employment	  status	  	   Patient	  endorses	  being	  employed	  in	  any	  
capacity	  at	  the	  time	  of	  induction	  	  
‘work,’	  ‘employment,’	  





Mood	  Stabilizer	  	  
At	  induction	  or	  any	  time	  during	  first	  month	  
of	  treatment	  	  
‘medications’	  	  
Buprenorphine	  Dose	   Initial	  per/day	  dose	  	   ‘medications’	  
Depression	   Axis	  I	  diagnosis	  of	  depression	  or	  presence	  
of	  ‘depression’	  on	  problem	  list	  	  
‘depression,’	  ‘depressed’	  	  
Anxiety	  Disorder	   Axis	  I	  diagnosis	  of	  anxiety	  or	  presence	  of	  
‘anxiety’	  on	  problem	  list	  
‘anxiety,’	  ‘panic,’	  ‘panic	  
attacks,’	  ‘generalized	  anxiety	  
disorder’	  	  
Bipolar	  Disorder	  	   Axis	  I	  diagnosis	  of	  bipolar	  or	  presence	  of	   ‘bipolar,’	  ‘mania,’	  ‘manic’	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‘bipolar’	  on	  problem	  list	  
Psychosis	   Axis	  I	  diagnosis	  of	  psychosis	  or	  presence	  of	  
‘psychosis’	  on	  problem	  list	  
‘psychosis,’	  ‘psychotic,’	  
‘schizophrenia’	  	  
PTSD	   Axis	  I	  diagnosis	  of	  PTSD	  or	  presence	  of	  
‘PTSD’	  on	  problem	  list	  
‘PTSD,’	  ‘trauma’	  	  
Chronic	  Pain	   History	  of	  chronic	  pain,	  or	  persistent	  
presence	  of	  ‘chronic	  pain’	  on	  problem	  list	  	  
‘chronic	  pain,’	  ‘pain’	  	  
Race	   White,	  Black,	  Latino,	  Asian,	  other	   ‘race’	  




Any	  history	  of	  time	  spent	  living	  on	  the	  
street,	  or	  otherwise	  without	  a	  home	  
‘homeless,’	  ‘street’	  	  
Participation	  in	  Drug	  
Counseling	  	  
Participation	  in	  >3	  sessions	  with	  an	  MGH	  
CHCC	  psychotherapist	  or	  social	  worker	  	  
Scrolled	  by	  date	  to	  find	  visit	  
notes,	  or	  ‘no	  show’	  notes	  	  
Participation	  in	  AA/NA	   Endorsed	  attendance	  at	  numerous	  AA/NA	  
meetings	  within	  first	  month	  of	  treatment.	  	  
‘aa,’	  ‘meetings,’	  ‘na’	  	  
HIV	  Seropositivity	  	   History	  of	  positive	  HIV	  Elisa	  or	  PCR	   ‘HIV,’	  ‘AIDS’	  	  
Hepatitis	  C	  
Seropositivity	  	  
History	  of	  positive	  Hepatitis	  C	  antibody	   ‘hepatitis,’	  ‘hepatitis	  c,’	  ‘hep	  c’	  	  
	  
Outcome	  measures	  	  	   All	  outcome	  measures	  were	  determined	  by	  the	  results	  of	  toxicology	  screens.	  Various	  toxicology	  screening	  methods	  were	  used	  over	  the	  past	  10	  years	  at	  the	  MGH	  CHCC,	  including	  urine,	  serum	  and	  saliva	  based	  tests.	  	  Data	  were	  collected	  for	  1	  year	  after	  the	  day	  patients	  began	  taking	  buprenorphine,	  unless	  treatment	  was	  discontinued	  or	  the	  patient	  was	  lost	  to	  follow-­‐up.	  The	  outcome	  observation	  period	  was	  broken	  up	  into	  two	  parts:	  the	  first	  8	  weeks,	  or	  ‘early	  treatment’	  period,	  and	  the	  following	  10	  months,	  or	  the	  ‘late	  treatment’	  period.	  During	  the	  first	  8	  weeks,	  data	  were	  collected	  about	  the	  absolute	  number	  of	  toxicology	  screens	  that	  a	  patient	  received,	  and	  also	  the	  number	  of	  those	  screens	  that	  were	  positive	  for	  opioids.	  ‘Positive’	  toxicology	  screens	  were	  defined	  as	  any	  that	  showed	  evidence	  of	  primary,	  non-­‐buprenorphine	  opioids	  in	  body	  fluids,	  including	  but	  not	  limited	  to	  heroin,	  oxycontin,	  oxycodone,	  hydrocodone,	  codeine,	  and	  methadone.	  Because	  opioid	  metabolites	  were	  not	  included	  in	  all	  toxicology	  screens,	  they	  were	  not	  used	  in	  this	  study	  as	  evidence	  of	  drug	  use.	  The	  number	  of	  toxicology	  screens	  which	  were	  positive	  for	  cocaine	  was	  also	  measured	  as	  a	  secondary	  outcome.	  The	  presence	  of	  other	  drugs,	  such	  as	  marijuana,	  benzodiazepines,	  and	  amphetamines	  were	  not	  included	  in	  the	  study.	  The	  toxicology	  screen	  administered	  on	  the	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day	  of	  buprenorphine	  induction	  was	  also	  excluded—nearly	  all	  screens	  are	  positive,	  and	  the	  information	  was	  thus	  of	  limited	  value.	  	  	  	  	   Based	  on	  their	  toxicology	  screens,	  all	  patients	  were	  subdivided	  into	  one	  of	  three	  primary	  outcome	  groups.	  Patients	  who	  were	  lost	  to	  follow-­‐up,	  or	  whose	  treatment	  was	  discontinued	  less	  than	  2	  months	  after	  induction	  were	  considered	  ‘early	  failures.’	  If	  patients	  attended	  appointments	  and	  were	  retained	  in	  care	  for	  at	  least	  8	  weeks,	  they	  were	  not	  considered	  early	  failures	  regardless	  of	  their	  toxicology	  screen	  results.	  This	  decision	  was	  made	  to	  account	  for	  those	  patients	  who	  exhibited	  a	  ‘slow’	  or	  ‘bumpy’	  start	  on	  buprenorphine	  therapy	  but	  later	  achieved	  sobriety.	  Patients	  who	  were	  retained	  in	  care	  for	  more	  than	  2	  months,	  but	  who	  then	  demonstrated	  ≥	  4	  positive	  toxicology	  screens	  during	  months	  2	  -­‐12	  were	  considered	  ‘late	  failures.’	  	  Patients	  whose	  care	  was	  discontinued,	  or	  those	  who	  were	  lost	  to	  follow-­‐up	  between	  months	  2-­‐12	  of	  treatment	  were	  also	  included	  in	  this	  group.	  The	  reasons	  why	  patients	  were	  lost	  to	  follow-­‐up	  were	  not	  accounted	  for	  in	  the	  study—if	  patients	  were	  not	  receiving	  toxicology	  screens	  at	  our	  institution,	  they	  were	  assumed	  to	  have	  relapsed.	  Finally,	  patients	  who	  were	  retained	  in	  care	  for	  1	  year	  with	  <4	  positive	  toxicology	  screens	  during	  the	  latter	  10	  months	  of	  treatment	  were	  considered	  successes.	  We	  thus	  posit	  that	  minimal	  drug	  use	  (rather	  than	  complete	  abstinence)	  constitutes	  success.	  This	  approach	  draws	  upon	  former	  studies	  that	  used	  less	  stringent,	  more	  attainable	  definitions	  success;	  these	  definitions	  reflect	  a	  significant	  reduction	  in	  risk	  behavior	  instead	  of	  ‘perfect	  performance,’	  and	  serve	  as	  more	  realistic	  target	  outcomes.18,19	  	  	  
TABLE	  3:	  	  OUTCOMES	  GROUPS	  DEFINED	  	  
Outcome	  Group	  	   	  	  	  	  	  	  	  	  Definition	  
Early	  Failure	  	   • Treatment	  discontinued	  at	  discretion	  of	  physician,	  OR	  patient	  lost	  to	  follow	  
up	  <	  8	  weeks	  after	  induction	  	  
	  
Late	  Failure	  	   • Treatment	  discontinued	  at	  discretion	  of	  physician,	  OR	  patient	  lost	  to	  follow-­‐
up	  >	  8	  weeks,	  but	  <1	  year	  after	  induction,	  OR	  
• Patients	  demonstrated	  ≥	  4	  positive	  toxicology	  screens	  for	  opioids	  between	  
8	  weeks	  and	  1	  year	  of	  treatment	  	  
	  
Success	  	  	   • Patient	  were	  retained	  in	  care	  for	  at	  least	  1	  year,	  with	  <	  4	  positive	  toxicology	  
screens	  during	  the	  latter	  10	  months	  of	  treatment	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IRB/Ethical	  considerations:	  	  This	  project	  was	  approved	  by	  the	  Harvard	  Human	  Research	  Protection	  Program	  on	  6/26/14,	  and	  by	  the	  MGH	  Internal	  Review	  Board	  on	  7/22/14.	  Since	  this	  project	  did	  not	  involve	  any	  human	  interaction	  or	  intervention,	  the	  main	  ethical	  consideration	  was	  privacy	  and	  identity	  protection.	  Because	  information	  about	  drug	  use/treatment,	  psychiatric	  history,	  and	  criminal	  history	  is	  highly	  sensitive,	  every	  possible	  effort	  was	  made	  to	  maintain	  the	  privacy	  of	  the	  patients	  from	  whom	  data	  were	  collected.	  Medical	  records	  and	  sensitive	  information	  was	  only	  accessed	  using	  secure,	  password-­‐protected,	  encrypted,	  and	  antivirus-­‐enabled	  computers,	  and	  all	  sensitive	  information	  was	  accessible	  only	  to	  the	  primary	  researchers	  on	  the	  project.	  No	  breaches	  of	  data	  occurred.	  	  	  
Data	  Analysis	  	  
	   After	  collaborative	  efforts	  were	  made	  to	  determine	  the	  best	  approach	  to	  statistical	  analysis,	  all	  statistical	  programming	  and	  data	  output	  was	  performed	  by	  Joseph	  Locascio,	  with	  the	  support	  of	  Harvard	  Catalyst.	  The	  data	  analysis	  was	  performed	  in	  two	  general	  steps:	  First,	  preliminary	  chi-­‐square	  tests	  and	  Fisher	  Exact	  tests	  were	  conducted	  to	  investigate	  the	  unadjusted	  relations	  of	  each	  categorical	  variable	  with	  the	  three	  outcome	  groups.	  T-­‐Tests	  or	  nonparametric	  tests	  (Mann-­‐Whitney,	  Kruskal-­‐Wallis)	  were	  used	  for	  relations	  of	  categorical	  to	  continuous	  numeric	  variables,	  and	  correlations	  were	  used	  for	  continuous	  vs.	  continuous	  assessments.	  This	  exploratory	  exercise	  allowed	  us	  to	  filter	  out	  the	  most	  significant	  predictive	  variables	  for	  more	  fine-­‐tuned,	  adjusted	  analysis. Based	  on	  those	  initial	  results,	  in	  order	  to	  test	  adjusted	  multivariate	  relations	  between	  sets	  of	  categorical	  and	  continuous	  predictors	  to	  the	  study	  outcome,	  we	  performed	  a	  series	  of	  logistic	  regression	  analyses	  where	  the	  dependent	  variable	  in	  each	  case	  was	  a	  binary	  comparison	  formed	  by	  a	  pair-­‐wise	  or	  pooled	  pair-­‐wise	  contrast	  of	  the	  three	  addiction	  treatment	  outcome	  groups:	  Early	  Failure,	  Late	  Failure,	  and	  Success.	  	  In	  the	  separate	  analyses,	  the	  binary	  comparisons	  were:	  (1)	  pooled	  Early	  Failure	  and	  Late	  Failure	  vs.	  Success,	  (2)	  Early	  Failure	  vs.	  pooled	  Late	  Failure	  and	  Success,	  and	  (3)	  Late	  Failure	  vs.	  Success,	  (omitting	  Early	  Failure).	  	  Each	  analysis	  employed	  a	  backward	  elimination	  algorithm	  using	  a	  cutoff	  of	  p=0.05.	  The	  set	  of	  initial	  predictors	  for	  the	  comparisons	  involving	  the	  pooled	  categories	  were:	  age,	  sex,	  injection	  drug	  use,	  non-­‐prescription	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buprenorphine	  use,	  employment,	  hepatitis	  C	  seropositivity,	  non-­‐prescription	  benzodiazepine	  use,	  years	  used,	  and	  participation	  in	  AA/NA.	  For	  the	  Late	  Failure	  vs.	  Success	  comparison,	  the	  predictors	  used	  were:	  percent	  early	  positive	  toxicology	  screens,	  drug	  counseling,	  injection	  drug	  use,	  hepatitis	  C	  positivity,	  cocaine	  use	  during	  treatment,	  employment,	  and	  participation	  in	  AA/NA.	  	  	  	  
III.	  Results	  	  
Demographics	  and	  Descriptive	  Statistics	  	  	   A	  total	  of	  160	  patients	  were	  included	  in	  the	  final	  study.	  Of	  them,	  104	  (65%)	  were	  male	  and	  56	  (35%)	  were	  female.	  Ages	  ranged	  from	  19-­‐63	  with	  an	  average	  of	  33.3.	  Patients	  had	  actively	  used	  opioids	  for	  an	  average	  of	  7	  years	  before	  presentation.	  152	  (95%)	  were	  white.	  Full	  data	  on	  all	  collected	  patient	  characteristics	  can	  be	  found	  in	  Table	  4,	  however	  a	  brief	  textual	  summary	  follows:	  90	  patients	  (56.3%)	  endorsed	  using	  injection	  drugs,	  and	  67	  (41.2%)	  endorsed	  using	  intranasally.	  Prior	  to	  induction,	  52	  (32.5%)	  endorsed	  actively	  using	  cocaine,	  35	  (21.9%)	  endorsed	  significant	  alcohol	  use,	  122	  (76.3%)	  were	  active	  cigarette	  smokers,	  66	  (41.3%)	  smoked	  marijuana,	  and	  45	  (28.1%)	  had	  used	  non-­‐prescription	  benzodiazepines.	  112	  (73.7%)	  had	  used	  non-­‐prescribed	  buprenorphine	  that	  they	  bought	  on	  the	  street.	  With	  respect	  to	  prior	  attempts	  at	  opioid	  abstinence,	  104	  (65.0%)	  had	  tried	  inpatient	  or	  intensive	  outpatient	  detoxification,	  35	  (21.9%)	  had	  tried	  methadone,	  and	  38	  (23.8%)	  had	  a	  prior	  attempt	  with	  buprenorphine.	  48	  (30.0%)	  endorsed	  a	  history	  of	  drug	  overdose.	  82	  (51.3%)	  were	  employed	  at	  the	  time	  of	  induction,	  58	  (36%)	  had	  been	  incarcerated	  in	  the	  past,	  and	  35	  (21.9%)	  had	  a	  history	  of	  homelessness.	  78	  (48.8%)	  carried	  a	  diagnosis	  of	  depression,	  66	  (41.3%)	  had	  an	  anxiety	  disorder,	  28	  (17.5%)	  had	  PTSD,	  and	  14	  (8.8%)	  had	  bipolar	  disorder.	  49	  (30.6%)	  suffered	  from	  chronic	  pain.	  90	  (56.3%)	  participated	  in	  in-­‐house	  drug	  counseling,	  and	  78	  (48.8%)	  participated	  in	  AA/NA.	  8	  (5.0%)	  were	  HIV-­‐positive,	  and	  75	  (46.9%)	  were	  seropositive	  for	  hepatitis	  C.	  	  	   With	  respect	  to	  the	  outcome	  variables,	  46	  (28.8%)	  were	  classified	  as	  early	  treatment	  failures,	  44	  (27.5%)	  were	  classified	  as	  late	  treatment	  failures,	  and	  70	  (43.75%)	  were	  classified	  as	  treatment	  successes	  at	  the	  end	  of	  1	  year.	  Early	  failures	  averaged	  30	  years	  of	  age,	  late	  failures	  averaged	  32	  years	  of	  age,	  and	  successes	  averaged	  36	  years	  of	  age.	  41	  patients	  (25.73%)	  regularly	  used	  cocaine	  during	  the	  treatment	  period.	  With	  respect	  to	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toxicology	  screens	  during	  the	  early	  treatment	  period,	  patients	  had	  an	  average	  of	  4.6	  screens	  each,	  and	  an	  average	  of	  1.1	  (23.9%)	  were	  positive	  for	  opiates.	  	  	  
Table	  4:	  DEMOGRAPHIC	  AND	  DESCRIPTIVE	  DATA	  	  
Variable	  (Numeric)	   Mean	  Value	  (Years)	   Range	  (Years)	  
Age	   33.3	   19-­‐63	  
Years	  of	  Active	  Drug	  Use	   7	  	   1-­‐35	  
Variable	  (Categorical)	   Number	  Positive	  	   Percent	  Positive	  	  
Sex	  (M)	  	   104	   65.0%	  
Sex	  (F)	  	   56	   35.0%	  
Injection	  Drug	  use	  	   90	   56.3%	  
Intranasal	  Drug	  use	   67	   41.2%	  
Active	  Cocaine	  use	  	   52	   32.5%	  
Active	  Alcohol	  use	  	   35	   21.9%	  
Cigarette	  use	   122	   76.3%	  
Marijuana	  use	   66	   41.3%	  
Non-­‐Rx	  Benzodiazepine	  use	  	   45	   28.1%	  
Non-­‐Rx	  Buprenorphine	  use	  	   118	   73.7%	  
Prior	  Buprenorphine	  attempt	   38	   23.8%	  
Prior	  Methadone	  attempt	  	   35	   21.9%	  
Prior	  Detox	  attempt	  	   104	   65.0%	  
History	  of	  Overdose	  	   48	   30.0%	  
Employment	  status	  	   82	   51.3%	  
Prescribed	  SSRI	  	   40	   25.0%	  
Prescribed	  Benzodiazepine	  	   17	   10.6%	  
Prescribed	  Gaba-­‐analogue	  	   19	   11.9%	  
Prescribed	  Antipsychotic	  	   12	   7.5%	  
Prescribed	  Mood	  Stabilizer	  	   5	   3.13%	  
Depression	   78	   48.8%	  
Anxiety	  Disorder	   66	   41.3%	  
Bipolar	  Disorder	  	   14	   8.8%	  
Psychosis	   5	   3.1%	  
PTSD	   28	   17.5%	  
Chronic	  Pain	   49	   30.6%	  
Race:	  White	   152	   95.0%	  
History	  of	  Incarceration	   58	   36.0%	  
History	  of	  Homelessness	   35	   21.9%	  
Drug	  Counseling	  	   90	   56.3%	  
Participation	  in	  AA/NA	   78	   48.8%	  
HIV	  Seropositivity	  	   8	   5.0%	  
Hepatitis	  C	  Seropositivity	  	   75	   46.9%	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Table	  5:	  OUTCOMES	  
Outcome	  Group	  	   Number	  	  	   Percent	  	  	   Avg.	  Age	  (years)	  
Early	  Failure	   46	   28.8%	   30	  
Late	  Failure	  	   44	   27.5%	   32	  
Success	   70	   43.75%	   36	  
	  
Unadjusted	  Predictive	  Relationships	  
	   Based	  on	  the	  number	  of	  ‘positive’	  responses	  received,	  a	  total	  of	  21	  variables	  were	  investigated	  for	  unadjusted	  predictive	  relationships	  to	  outcomes.	  Of	  these,	  5	  variables	  achieved	  significance	  at	  the	  p<.05	  level:	  Injection	  Drug	  Use,	  use	  of	  street	  buprenorphine,	  employment,	  attendance	  in	  drug	  counseling,	  and	  hepatitis	  C	  positivity.	  Accounting	  for	  multiple	  tests	  and	  using	  a	  more	  stringent	  p	  value	  of	  	  <.01,	  all	  variables	  but	  use	  of	  street	  buprenorphine	  remained	  significant.	  Importantly,	  these	  p	  values	  merely	  reflect	  the	  
distribution	  of	  variables,	  and	  do	  not	  contain	  information	  about	  the	  direction	  of	  trends.	  	  	  
	  
Table	  6:	  UNADJUSTED	  RELATIONSHIPS	  OF	  PATIENT	  CHARACTERISTICS	  BY	  OUTCOME	  	  
Variable	   N	   Early	  Failure	  	  (%)	   Late	  Failure	  (%)	   Success	  (%)	   P	  value	  
OVERALL	   160	   46	  (28.8)	   44	  (27.5)	   70	  (43.8)	   	  
	   	   	   	   	   	  
Sex	  (m)	   104	   35	  (33.7)	   29	  (27.9)	   40	  (38.5)	   .11	  
Sex	  (f)	   56	   11	  (19.6)	   15	  (26.8)	   30	  (53.6)	  
	   	   	   	   	   	  
Injection	  Users	   90	   32	  (35.6)	   30	  (33.3)	   28	  (31.1)	   .0012	  
Non-­‐Inj.	  Users	   70	   14	  (20.0)	   14	  (20.0)	   42	  (60.0)	  
	   	   	   	   	   	  
Intranasal	  Users	   67	   20	  (29.9)	   18	  (26.9)	   29	  (43.2)	   .97	  
Non-­‐In.	  Users	   93	   26	  (27.9)	   26	  (27.9)	   	  41	  (44.2)	  
	   	   	   	   	   	  
Cocaine	  Users	   52	   17	  (32.7)	   17	  (32.7)	   18	  (34.6)	   .26	  
Non-­‐Cocaine	  Users	   108	   29	  (26.8)	   27	  (25.0)	   52	  (48.2)	  
	   	   	   	   	   	  
Alcohol	  Users	   35	   11	  (31.4)	   13	  (37.1)	   11	  (31.4)	   .20	  
Non-­‐Alcohol	  Users	   125	   35	  (28.0)	   31	  (24.8)	   59	  (47.2)	  
	   	   	   	   	   	  
Smokers	   122	   36	  (29.5)	   36	  (29.5)	   50	  (41.0)	   .42	  
Non-­‐Smokers	   38	   10	  (26.3)	   8	  (21.1)	   20	  (52.6)	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MJ	  Smokers	   66	   22	  (33.3)	   22	  (33.3)	   22	  (33.3)	  	   .082	  
Non-­‐	  MJ	  Smokers	   94	   24	  (25.3)	   22	  (23.4)	  	   48	  (51.1)	  
	   	   	   	   	   	  
Benzo	  Users	   45	   17	  (37.8)	   15	  (33.3)	   13	  (28.9)	   .058	  
Non-­‐Benzo	  Users	   115	   29	  (25.2)	  	   29	  (25.2)	   57	  (29.6)	  
	   	   	   	   	   	  
‘Street’	  Bup	  Users	   118	   31	  (26.3)	   39	  (33.1)	   48	  (40.7)	   .031	  
Never	  Users	  	   42	   15	  (35.7)	  	   5	  (11.9)	   22	  (52.4)	  
	   	   	   	   	   	  
Prior	  Bup	  Atmpt	   38	   11	  (28.9)	   12	  (31.5)	   15	  (39.5)	   .78	  
1st	  Bup	  Atmpt	   122	   35	  (28.7)	   32	  (26.2)	   55	  (45.1)	  
	   	   	   	   	   	  
History	  of	  OD	   48	   16	  	  (33.3)	   16	  (33.3)	   16	  (33.3)	   .22	  
No	  History	  of	  OD	   112	   30	  (26.7)	   28	  (25.0)	   54	  (48.2)	  
	   	   	   	   	   	  
Employed	   82	   15	  (18.3)	   23	  (29.1)	   44	  (53.7)	   .006	  
Unemployed	   78	   31(39.7)	   21	  (26.9)	   26	  (33.3)	  
	   	   	   	   	   	  
Depressed	   78	   19	  (24.4)	   24	  (30.8)	   35	  (44.9)	   .44	  
Not-­‐Depressed	   82	   27	  (32.9)	   20	  (24.4)	   35	  (42.7)	  
	   	   	   	   	   	  
Anxiety	  Disorder	   66	   16	  (20.2)	   18	  (27.3)	   32	  (48.8)	   .50	  
No	  Anx.	  Disorder	   94	   30	  (31.9)	   26	  (27.7)	   38	  (40.4)	  
	   	   	   	   	   	  
PTSD	   28	   6	  (21.43)	   11	  (39.3)	   11	  (39.3)	   .29	  
No	  PTSD	   132	   40	  (30.3)	   33	  (25.0)	   59	  (44.7)	  	  
	   	   	   	   	   	  
Chronic	  Pain	   49	   8	  (16.3)	   	   17	  (34.7)	   24	  (50.0)	   .0620	  
No	  Chronic	  Pain	   111	   38	  (34.2)	   27	  (24.3)	   46	  (41.4)	  
	   	   	   	   	   	  
Past	  Incarceration	   58	   20	  (34.5)	   18	  (31.0)	   20	  (34.5)	   .19	  
No	  Past	  Incarc.	  	   102	   26	  (25.5)	   26	  (25.5)	   50	  (49.0)	  
	   	   	   	   	   	  
Once	  Homeless	   35	   10	  (28.6)	   9	  (25.7)	   16	  (45.7)	   .95	  
Never	  Homeless	   125	   36	  (28.8)	   35	  (28.0)	   54	  (43.2)	  
	   	   	   	   	   	  
Drug	  Counseling	   90	   16	  (17.8)	   21	  (23.3)	   53	  (58.9)	   <.0001	  
No	  Drug	  Counsel.	   70	   30	  (42.9)	   23	  (32.9)	   17	  (24.3)	  
	   	   	   	   	   	  
AA/NA	  Attenders	   78	   16	  (20.5)	   24	  (30.8)	   38	  (48.7)	   .08	  
No	  AA/NA	   82	   30	  (36.6)	   20	  (24.4)	   32	  (39.0)	  
	   	   	   	   	   	  
Hep	  C	  Positive	   75	   27	  	  (36.0)	   25	  	  (33.3)	   23	  (30.7)	   .0073	  
Not	  Hep	  C.	  Pos	   85	   19	  (22.4)	   19	  (22.4)	   47	  (55.2)	  
 
	  
	   17	  
Logistic	  Regression	  for	  Adjusted	  Predictors	  	  
	   Three	  logistic	  regression	  models	  were	  run.	  They	  are	  presented	  below	  in	  order,	  accompanied	  by	  charts	  summarizing	  the	  backward	  elimination	  process,	  and	  graphic	  depictions	  of	  their	  respective	  predictive	  models.	  	  
	  1.	  Success	  vs.	  Early	  or	  Late	  Failure	  	  
	   For	  the	  logistic	  regression	  whose	  outcome	  comparison	  was	  pooled	  early	  failures	  and	  late	  failures	  vs.	  success,	  the	  final	  reduced	  model	  included	  the	  predictors	  Age	  (p=	  .0013),	  Sex	  (p=	  .0200),	  Employment	  (p=	  .0131),	  and	  Hepatitis	  C	  seropositivity	  (p	  =	  .0062).	  	  Age,	  employment,	  and	  female	  sex	  were	  all	  correlated	  positively	  with	  success.	  Having	  hepatitis	  C	  was	  correlated	  with	  failure.	  Odds	  ratio	  estimates	  with	  confidence	  intervals	  (CIs)	  follow:	  For	  every	  additional	  decade	  of	  age,	  individuals	  were	  1.7x	  more	  likely	  to	  respond	  successfully	  to	  treatment	  (CI	  1.25-­‐2.47).	  	  Women	  were	  2.42x	  more	  likely	  than	  men	  to	  be	  successful	  (CI	  1.16-­‐5.18).	  	  Those	  who	  were	  employed	  at	  the	  time	  of	  induction	  were	  2.48x	  more	  likely	  to	  be	  successful	  	  (CI	  1.22-­‐5.1).	  Finally,	  those	  who	  were	  seropositive	  for	  hepatitis	  C	  were	  2.70x	  more	  likely	  to	  be	  in	  the	  early	  or	  late	  failure	  group	  (CI	  1.33-­‐5.56).	  The	  area	  under	  the	  ROC	  curve	  for	  this	  model	  was	  .736.	  	  
	  
Table	  7:	  SUMMARY	  OF	  BACKWARD	  ELIMINATION:	  SUCCESS	  vs.	  FAILURE	  AT	  ANY	  TIME	  
Elimination	   Variable	   P	  value	   Predicts	   Odds	  Ratio	   Confidence	  Interval	  
1	   Years	  Used	   0.8635	   	   Eliminated	   	  
2	   Streep	  Bup	   0.3855	   	   Eliminated	   	  
3	   AA/NA	   0.2573	   	   Eliminated	   	  
4	   Non-­‐Rx	  Benzo	   0.2920	   	   Eliminated	   	  
5	   Inj.	  Drug	  Use	   0.1524	   	   Eliminated	   	  
Sustained	   Age	  (Decades)	   0.0013	   Success	   1.74	   1.25-­‐2.47	  
Sustained	   Sex	  (Female)	   0.0200	   Success	   2.42	   1.16-­‐5.18	  
Sustained	   Employment	   0.0131	   Success	   2.48	   1.22-­‐5.1	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Figure	  1:	  PREDICTIVE	  MODEL	  FOR	  SUCCESS	  (vs.	  FAILURE	  AT	  ANY	  TIME)	  **See	  appendix	  for	  legend	  	  
	  
	  2.	  Early	  Failure	  vs.	  Pooled	  Late	  Failure/Success	  (Treatment	  Retention)	  	  For	  the	  logistic	  regression	  whose	  outcome	  comparison	  was	  early	  failure	  versus	  pooled	  late	  failures	  and	  success,	  the	  final	  reduced	  model	  included	  the	  predictors:	  Age	  (p=	  .0197),	  Sex	  (p=	  .0123),	  and	  Employment	  (p=0.0011).	  Increased	  age,	  female	  sex,	  and	  employment	  were	  all	  correlated	  with	  treatment	  retention	  greater	  than	  2	  months.	  Conversely,	  young	  age,	  male	  sex,	  and	  unemployment	  were	  specifically	  associated	  with	  early	  failure.	  For	  every	  additional	  decade	  of	  age,	  patients	  were	  1.55x	  more	  likely	  to	  successfully	  exhibit	  treatment	  retention	  past	  the	  early	  phase	  (CI	  1.09-­‐2.29).	  Females	  were	  2.99x	  as	  likely	  to	  achieve	  treatment	  retention	  (CI	  1.29-­‐6.99),	  and	  those	  who	  were	  employed	  were	  3.59x	  as	  likely	  to	  achieve	  treatment	  retention	  (CI	  1.70-­‐7.92).	  The	  area	  under	  the	  ROC	  curve	  for	  this	  model	  was	  .715.	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Table	  8:	  SUMMMARY	  OF	  BACKWARD	  ELIMINATION:	  TREATMENT	  RETENTION	  >	  8	  WEEKS	  
Elimination	   Variable	   P	  value	   Predicts	   Odds	  Ratio	   Confidence	  Interval	  	  
1	   Years	  Used	   0.9958	   	   Eliminated	   	  
2	   Non	  Rx	  Benzo	   0.4843	   	   Eliminated	   	  
3	   Inj.	  Drug	  Use	   0.4484	   	   Eliminated	   	  
4	   Street	  Bup	   0.1736	   	   Eliminated	   	  
5	   Hep	  C	  Pos	   0.1387	   	   Eliminated	   	  
6	   AA/NA	   0.1820	   	   Eliminated	   	  
Sustained	   Age	  (decades)	   0.0197	   Retention	  	   1.55	   1.09-­‐2.29	  
Sustained	   Sex	  (F)	   0.0123	   Retention	   2.99	   1.29-­‐6.99	  
Sustained	   Employment	   0.0011	   Retention	   3.59	   1.70-­‐7.92	  	  
Figure	  2:	  PREDICTIVE	  MODEL	  FOR	  TREATMENT	  RETENTION	  >	  8	  WEEKS	  **See	  appendix	  for	  legend	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3.	  Late	  Failures	  vs.	  Success	  (excluding	  Early	  Failures)	  
	   Finally,	  for	  the	  logistic	  regression	  whose	  outcome	  comparison	  was	  Late	  Failures	  vs.	  Successes	  (excluding	  early	  failures),	  the	  final	  reduced	  model	  included	  the	  predictors:	  Early	  Percent	  Positive	  Toxicology	  Screens	  (p=.001),	  Participation	  in	  Drug	  Counseling	  (p=.002),	  and	  Injection	  Drug	  Use	  (p=.010).	  Increased	  percentage	  early	  positive	  drug	  screens	  and	  history	  of	  Injection	  Drug	  Use	  were	  both	  significantly	  predictive	  of	  late	  failure.	  Participation	  in	  Drug	  Counseling	  was	  significantly	  predictive	  of	  success.	  For	  every	  additional	  25%	  of	  early	  toxicology	  screens	  that	  were	  positive,	  patients	  were	  predicted	  to	  be	  2.2x	  more	  likely	  to	  fall	  into	  the	  late	  failure,	  rather	  than	  the	  success	  group	  (CI	  1.42-­‐3.70).	  Participation	  in	  Drug	  Counseling	  made	  it	  4.3x	  more	  likely	  that	  patients	  would	  fall	  into	  the	  success	  group,	  rather	  than	  the	  late	  failure	  group	  (CI	  1.76-­‐11.58).	  Finally,	  patients	  who	  had	  a	  history	  of	  Injection	  Drug	  Use	  were	  3.28x	  more	  likely	  to	  be	  late	  failures,	  rather	  than	  successes	  (1.35-­‐8.40).	  The	  area	  of	  the	  ROC	  curve	  for	  this	  predictive	  model	  is	  .801.	  	  	  
TABLE	  9:	  	  SUMMARY	  OF	  BACKWARD	  ELIMINATION:	  LATE	  FAILURE	  vs.	  SUCCESS	  	  
Elimination	   Variable	   P	  value	   Predicts	   Odds	  Ratio	   Confidence	  Interval	  
1	   Tx	  Cocaine	   0.9836	   	   Eliminated	   	  
2	   AA/NA	   0.5949	   	   Eliminated	   	  
3	   Employment	   0.5532	   	   Eliminated	   	  
4	   Hepatitis	  C	   0.2152	   	   Eliminated	   	  
Sustained	   Early	  %	  Pos	  (25%)	   0.0010	   Failure	   2.21	   1.42-­‐3.70	  
Sustained	   Drug	  Counseling	   0.0020	   Success	   4.36	   1.76-­‐11.58	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Demographic/Unadjusted	  Results	  in	  Context	  	  	   First,	  with	  respect	  to	  demographics,	  our	  population	  very	  closely	  mirrors	  that	  described	  by	  the	  2014	  JAMA	  study	  documenting	  the	  changing	  face	  of	  opioid	  addiction.	  Both	  reflect	  a	  population	  of	  >90%	  white	  individuals	  in	  their	  late	  20’s/early	  30’s,	  living	  in	  urban/suburban	  regions.15	  Interestingly,	  the	  fact	  that	  nearly	  50%	  of	  our	  patients	  had	  never	  tried	  injection	  drugs	  reflects	  the	  concurrent	  evolution	  of	  opioid	  addiction	  towards	  prescription	  medications.20	  As	  expected,	  our	  population	  also	  exhibits	  higher	  rates	  of	  other	  recreational	  drug	  use,	  mental	  illness,	  history	  of	  incarceration,	  and	  markers	  of	  lower	  socio-­‐economic	  status	  (unemployment,	  history	  of	  homelessness)	  than	  the	  general	  population.	  	  Of	  particular	  interest	  are	  the	  rates	  of	  drug-­‐associated	  infectious	  diseases	  in	  this	  population:	  while	  only	  8	  patients	  (5%	  of	  our	  population)	  were	  HIV	  positive,	  75	  (46.9%)	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were	  hepatitis	  C	  positive.	  This	  reflects	  a	  concerning	  national	  trend.	  There	  has	  been	  a	  significant	  increase	  in	  the	  prevalence	  of	  hepatitis	  C	  in	  young,	  suburban,	  injection	  drug	  users,	  and	  disease	  and	  death	  resulting	  from	  hepatitis	  C	  infection	  in	  the	  United	  States	  has	  recently	  surpassed	  that	  caused	  by	  HIV.21	  	  In	  our	  study,	  90	  patients	  had	  used	  injection	  drugs,	  and	  of	  them	  64	  (71%)	  were	  hepatitis	  C	  positive.	  Only	  11	  patients	  who	  were	  hepatitis	  C	  positive	  denied	  injection	  drug	  use,	  which	  may	  represent	  underreporting	  plus	  hepatitis	  C	  from	  other	  causes,	  such	  as	  intranasal	  use	  or	  sexual	  contact.	  Rates	  of	  hepatitis	  C	  at	  this	  high	  level	  are	  uncommon,	  but	  have	  been	  reported	  elsewhere	  in	  the	  literature.22	  The	  overall	  rates	  of	  successful	  response	  to	  buprenorphine	  (in	  our	  study:	  43.75%)	  are	  comparable	  to	  prior	  studies	  done	  in	  this	  area.	  For	  example,	  our	  rates	  are	  slightly	  lower	  than	  the	  smaller	  2007	  study	  examining	  an	  overlapping	  population,	  which	  found	  a	  54%	  success	  rate	  at	  6	  months.11	  Of	  course,	  success	  rates	  depend	  intrinsically	  on	  how	  studies	  define	  ‘success,’	  in	  that	  studies	  using	  longer	  follow-­‐up	  periods	  are	  likely	  to	  define	  fewer	  individuals	  as	  successful.	  Further,	  because	  individuals	  who	  left	  treatment	  were	  counted	  as	  ‘failures’	  regardless	  of	  their	  reasons	  for	  leaving,	  it	  is	  possible	  that	  some	  patients	  in	  our	  early	  or	  late	  failure	  groups	  actually	  maintained	  sobriety	  on	  their	  own,	  or	  under	  the	  care	  of	  non-­‐MGH	  CHCC	  physicians.	  	  Importantly,	  in	  our	  study,	  rates	  of	  success	  varied	  dramatically	  across	  specific	  demographic	  groups.	  For	  example,	  the	  average	  male	  had	  a	  38.5%	  chance	  of	  success,	  whereas	  the	  average	  female	  had	  a	  53.6%	  chance	  of	  success.	  Patients	  with	  a	  history	  of	  injection	  drug	  use	  had	  a	  31.1%	  chance	  of	  success,	  and	  those	  who	  were	  unemployed	  had	  a	  33.3%	  chance	  of	  success.	  	  Those	  with	  hepatitis	  C	  had	  a	  30.7%	  chance,	  and	  those	  who	  did	  not	  attend	  early	  drug	  counseling	  meetings	  had	  only	  a	  24.3%	  chance	  of	  success.	  	  With	  respect	  to	  the	  probability	  of	  early	  failure	  specifically,	  compared	  with	  a	  baseline	  overall	  average	  rate	  of	  28.8%,	  people	  who	  used	  recreational	  benzodiazepines	  had	  a	  37.8%	  chance	  of	  failing	  treatment	  in	  the	  first	  8	  weeks.	  Those	  who	  did	  not	  attend	  drug	  counseling	  had	  a	  43.9%	  chance	  of	  falling	  into	  this	  group.	  On	  the	  other	  hand,	  those	  who	  were	  employed	  at	  the	  time	  of	  induction	  only	  had	  an	  18.3%	  chance	  of	  early	  failure.	  Patients	  with	  chronic	  pain	  had	  only	  a	  16.3%	  chance	  of	  failing	  early,	  and	  those	  who	  attended	  AA/NA	  had	  only	  a	  20.5%	  chance.	  Interestingly,	  those	  who	  were	  most	  likely	  to	  fall	  into	  the	  ‘late	  failure’	  group	  were	  regular	  Alcohol	  Users	  (37.1%)	  and	  those	  with	  PTSD	  (39.3%).	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It	  is	  important	  to	  interpret	  all	  of	  these	  data	  with	  care.	  While	  these	  unadjusted	  results	  are	  predictive	  (especially	  those	  which	  reached	  significance),	  it	  is	  impossible	  to	  tell	  which	  variables	  are	  operative	  with	  respect	  to	  the	  outcome.	  In	  order	  to	  parse	  the	  independent	  contributions	  of	  each	  variable	  to	  the	  outcome	  group,	  and	  to	  see	  how	  the	  probability	  of	  a	  particular	  outcome	  is	  effected	  by	  overlapping	  characteristics,	  it	  is	  necessary	  to	  invoke	  logistic	  models.	  	  
Adjusted	  Logistic	  Regressions:	  Interpretation	  1.	  Predictors	  of	  Success	  over	  Failure	  at	  any	  Time	  	   This	  grouping	  reflects	  the	  traditional	  success/failure	  dichotomy	  used	  by	  nearly	  all	  prior	  studies,	  and	  answers	  the	  question:	  What	  are	  the	  predictors	  that	  a	  patient	  will	  be	  successful	  at	  the	  end	  of	  one	  year	  of	  therapy?	  Our	  study	  suggests	  that	  older	  employed	  females	  with	  no	  history	  of	  hepatitis	  C	  have	  the	  greatest	  chance	  of	  successful	  response	  to	  buprenorphine.	  Conversely,	  younger,	  unemployed	  males	  with	  hepatitis	  C	  have	  the	  smallest	  chance	  of	  success.	  According	  to	  the	  predictive	  model,	  a	  20-­‐year-­‐old	  unemployed	  male	  with	  hepatitis	  C	  has	  an	  estimated	  <10%	  chance	  of	  successful	  response	  to	  treatment.	  On	  the	  other	  hand,	  an	  employed	  50	  year	  old	  woman	  with	  no	  hepatitis	  C	  history	  has	  >80%	  chance	  of	  succeeding.	  	  	   Age	  and	  employment	  are	  both	  documented	  predictors	  of	  successful	  response	  to	  medical	  treatment	  of	  opioid	  addiction.	  11,13,14	  However,	  far	  fewer	  studies	  have	  uncovered	  an	  independent	  connection	  between	  Hepatitis	  C	  and	  response	  to	  opioid	  replacement	  therapy.	  In	  one	  example,	  a	  study	  published	  in	  early	  2015	  investigated	  data	  from	  the	  National	  Drug	  Abuse	  Treatment	  Clinical	  Trial	  Network,	  and	  found	  that	  patients	  with	  HCV	  seropositivity	  were	  less	  likely	  to	  submit	  opioid	  negative	  urines	  during	  or	  after	  treatment	  with	  buprenorphine.23	  It	  is	  notable	  that	  injection	  drug	  use	  was	  eliminated	  from	  this	  backward	  prediction	  model	  with	  a	  p	  value	  of	  .1524.	  What	  is	  it	  about	  hepatitis	  C	  itself	  that	  portends	  failure?	  Our	  interpretation	  is	  that	  the	  relationship	  is	  not	  a	  consequence	  the	  disease,	  but	  rather	  a	  function	  of	  the	  risks	  associated	  with	  hepatitis	  C	  exposure.	  In	  most	  circumstances,	  hepatitis	  C	  among	  injection	  drug	  users	  results	  from	  unsafe	  needle	  practices,	  such	  as	  sharing	  needles/cottons/cookers.	  It	  is	  possible	  that	  individuals	  who	  have	  resorted	  to	  using	  unsafe	  needle	  practices	  share	  certain	  personal	  or	  psychosocial	  characteristics,	  which	  also	  make	  it	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harder	  to	  overcome	  addiction.	  Possible	  candidates	  for	  such	  a	  characteristic	  include	  desperation	  to	  use	  despite	  inappropriate	  equipment	  (a	  possible	  reflection	  of	  the	  strong	  grip	  of	  addiction),	  a	  reckless/risk	  avid	  personality	  type,	  or	  socioeconomic	  inability	  to	  procure	  clean	  supplies.	  	  	  2.	  Early	  Failure	  vs.	  Treatment	  Retention	  >	  8	  weeks	  	  	   This	  analysis	  dichotomized	  all	  individuals	  who	  failed	  during	  the	  first	  8	  weeks	  of	  treatment	  (Early	  Failures),	  against	  those	  who	  were	  successfully	  retained	  past	  two	  months	  of	  treatment,	  regardless	  of	  the	  ultimate	  outcome.	  It	  was	  designed	  to	  answer	  the	  question:	  How	  can	  we	  predict	  which	  people	  are	  at	  the	  highest	  risk	  of	  early	  failure?	  Or,	  how	  can	  we	  predict	  who	  has	  a	  better	  chance	  of	  treatment	  retention?	  Our	  study	  suggests	  that	  a	  simple	  model	  of	  age,	  sex,	  and	  employment	  is	  sufficient	  to	  predict	  probability	  of	  early	  failure.	  Those	  who	  are	  young,	  male,	  and	  unemployed	  are	  at	  the	  highest	  risk	  in	  the	  early	  period,	  such	  that	  a	  20	  year	  old,	  unemployed	  male	  has	  a	  >65%	  chance	  of	  failing	  treatment	  during	  the	  first	  eight	  weeks.	  This	  result	  supports	  and	  validates	  the	  results	  of	  the	  prior	  regression,	  in	  which	  young	  unemployed	  males	  were	  found	  to	  be	  in	  the	  highest	  risk	  group.	  However,	  in	  this	  test,	  injection	  drug	  use	  rather	  than	  hepatitis	  C	  status	  was	  found	  to	  have	  predictive	  relevance.	  	  	   Why	  is	  injection	  drug	  use	  a	  predictor	  for	  early	  failure?	  The	  above	  hypotheses	  invoked	  to	  explain	  the	  role	  of	  hepatitis	  C	  may	  be	  relevant.	  However,	  there	  are	  additional	  factors	  that	  may	  also	  be	  at	  play,	  for	  example,	  the	  rapidity	  by	  which	  an	  injected	  drug	  reaches	  the	  brain,	  producing	  the	  characteristic	  quick	  intense	  feeling	  of	  euphoria,	  followed	  (especially	  in	  the	  case	  of	  injected	  heroin)	  by	  the	  rapid	  metabolism	  of	  the	  drug	  and	  the	  onset	  of	  withdrawal.	  These	  differing	  pharmacodynamic	  properties	  of	  injection	  drugs	  likely	  contribute	  to	  a	  documented	  increase	  in	  their	  addictive	  potential.24	  Additionally,	  the	  act	  of	  injecting	  drugs	  may	  be	  elevated	  to	  a	  ritualistic	  behavior	  by	  some	  individuals—one	  that	  is	  an	  integral	  part	  of	  the	  totality	  of	  addiction.	  While	  patients	  who	  use	  oral	  opioids	  may	  find	  a	  more	  natural,	  analogous	  opioid	  replacement	  in	  a	  pill	  of	  buprenorphine,	  patients	  who	  are	  accustomed	  to	  injecting	  might	  not	  get	  the	  same	  satisfaction.	  An	  analogy	  can	  be	  drawn	  between	  this	  phenomena	  and	  that	  of	  why	  some	  cigarette	  smokers	  may	  have	  trouble	  quitting	  simply	  by	  using	  a	  nicotine	  patch;	  merely	  replacing	  the	  biochemical	  drug	  medically	  may	  not	  be	  sufficient,	  insofar	  as	  addiction	  extends	  beyond	  pure	  biochemical	  dependence	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into	  a	  more	  complex,	  biopsychosocial	  realm.	  Importantly,	  our	  study	  does	  not	  suggest	  that	  injection	  drug	  users	  would	  be	  better	  off	  taking	  other	  forms	  of	  opioid	  replacement	  therapy—instead,	  it	  only	  suggests	  that	  independent	  of	  other	  factors,	  those	  patients	  have	  the	  highest	  risk	  of	  early	  failure	  when	  taking	  buprenorphine.	  	  	  3.	  Late	  Failures	  vs.	  Successes	  	   This	  model,	  which	  excluded	  the	  early	  failures,	  was	  designed	  to	  find	  early	  predictors	  that	  might	  be	  able	  to	  portend	  failure	  later	  in	  treatment,	  among	  those	  patients	  who	  were	  successfully	  retained	  past	  the	  first	  eight	  weeks.	  Indeed,	  approximately	  50%	  of	  patients	  who	  failed	  treatment	  did	  so	  in	  the	  latter	  10	  months	  of	  care,	  indicating	  that	  patients	  are	  still	  at	  significant	  risk	  after	  they	  surpass	  the	  early	  stage	  of	  treatment.	  Our	  findings	  suggest	  that	  three	  variables	  function	  as	  successful	  predictors	  of	  this	  later	  failure:	  Percentage	  positive	  early	  toxicology	  screens,	  participation	  in	  drug	  counseling,	  and	  injection	  drug	  use.	  	  First,	  the	  higher	  the	  percentage	  of	  toxicology	  screens	  during	  the	  first	  8	  weeks	  of	  treatment	  that	  were	  positive,	  the	  more	  likely	  patents	  were	  to	  fall	  in	  the	  late	  failure	  group.	  This	  result	  suggests	  that	  patients	  who	  exhibited	  difficulty	  in	  attaining	  abstinence	  early	  on	  are	  at	  higher	  risk	  for	  relapse	  or	  failure	  later	  on.	  These	  results	  indicate	  that	  those	  factors	  which	  cause	  a	  given	  patient	  to	  have	  a	  slow	  or	  difficult	  time	  adjusting	  to	  sobriety/buprenorphine	  therapy	  probably	  remain	  present	  and	  relevant	  during	  the	  entire	  treatment	  period.	  At	  least	  one	  other	  study	  has	  corroborated	  this	  result,	  showing	  that	  response	  after	  as	  little	  as	  two	  weeks	  of	  therapy	  is	  sufficient	  to	  predict	  performance	  after	  12	  weeks	  of	  treatment.25	  Finally,	  participation	  in	  drug	  counseling	  is	  a	  strong	  positive	  predictive	  factor	  for	  long-­‐term	  success.	  This	  shows	  that	  patients	  who	  attended	  3	  or	  more	  sessions	  in	  the	  first	  1-­‐2	  months	  of	  treatment	  were	  4.5x	  more	  likely	  to	  succeed.	  The	  role	  of	  drug	  counseling	  is	  thus	  far	  unsettled	  in	  the	  literature.	  One	  retrospective	  secondary	  analysis	  found	  a	  modest	  benefit	  of	  counseling	  specifically	  among	  injection	  drug	  users,	  but	  only	  those	  who	  were	  also	  adherent	  to	  treatment.26	  However,	  a	  2011	  multisite	  randomized	  controlled	  trial	  found	  no	  difference	  between	  the	  outcomes	  in	  counseling	  vs.	  no-­‐counseling	  groups.19	  Another	  recent	  randomized	  trial	  investigated	  the	  role	  of	  a	  specific,	  new	  therapeutic	  approach	  and	  failed	  to	  find	  significant	  differences	  between	  groups	  who	  were	  or	  were	  not	  exposed	  to	  therapy.27	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One	  issue	  with	  this	  particular	  research	  question	  is	  that	  there	  is	  no	  standardized	  protocol	  for	  clinic	  or	  hospital	  based	  therapy	  sessions—‘therapy’	  or	  ‘counseling’	  can	  mean	  widely	  divergent	  things.	  Even	  within	  this	  study,	  the	  content	  of	  counseling	  appointments	  was	  diverse,	  including	  both	  individual	  and	  group	  sessions,	  with	  varying	  emphasis	  on	  mental	  illness	  and	  psychopharmacology	  versus	  simply	  social	  or	  economic	  issues.	  In	  any	  case,	  it	  is	  clear	  that	  in	  our	  cohort,	  at	  the	  very	  least,	  willingness	  to	  participate	  in	  therapy	  sessions	  is	  a	  positive	  prognostic	  indicator.	  At	  the	  most,	  participation	  in	  therapy	  provided	  patients	  with	  support	  and/or	  tools	  that	  they	  could	  use	  to	  avoid	  the	  mental	  or	  physical	  states	  and	  environments	  that	  put	  them	  at	  risk	  of	  using	  drugs	  again.	  	  	  
Learning	  from	  Non-­‐Predictive	  Variables	  	   In	  addition	  to	  investigating	  the	  predictive	  variables,	  it	  is	  important	  to	  also	  take	  stock	  of	  all	  of	  the	  variables	  that	  were	  not	  predictive—those	  which	  had	  no	  statistical	  relationship	  with	  outcomes.	  Of	  special	  note,	  the	  use	  of	  any	  other	  drugs	  (alcohol,	  cocaine,	  cigarettes,	  marijuana,	  benzodiazepines)	  either	  prior	  to	  or	  during	  the	  study	  (in	  the	  case	  of	  cocaine)	  predicted	  success	  or	  failure.	  While	  the	  practice	  in	  the	  clinic	  was	  to	  discourage	  all	  other	  drug	  use	  (especially	  the	  use	  of	  substances	  which	  might	  lower	  the	  inhibitions	  of	  the	  user,	  such	  as	  alcohol	  or	  benzodiazepines),	  this	  result	  suggests	  that	  patients	  were	  just	  as	  likely	  to	  achieve	  success	  regardless	  of	  whether	  they	  had	  used	  non-­‐opioid	  drugs.	  Also,	  it	  was	  not	  common	  practice	  to	  discontinue	  care	  based	  solely	  on	  positive	  toxicology	  screens	  for	  cocaine	  or	  marijuana;	  these	  results	  help	  to	  validate	  that	  practice	  as	  a	  reasonable	  harm	  reduction	  technique.	  Next,	  while	  mental	  health	  comorbidities	  were	  highly	  overrepresented	  in	  our	  population,	  neither	  psychiatric	  diagnoses	  nor	  the	  medications	  used	  to	  treat	  them	  provided	  predictive	  value	  in	  this	  model.	  It	  is	  important	  to	  mention	  that	  mental	  health	  problems	  can	  be	  difficult	  to	  parse	  from	  addiction	  itself—many	  DSM	  criteria	  purposefully	  exclude	  diagnoses	  that	  could	  be	  attributed	  to	  substance	  use	  rather	  than	  organic	  causes.	  Despite	  this,	  our	  results	  cast	  an	  optimistic	  light	  on	  the	  prospects	  of	  individuals	  who	  suffer	  from	  concurrent	  mental	  illness	  and	  addiction.	  	  ‘Years	  of	  active	  drug	  use’	  was	  also	  non-­‐predictive,	  perhaps	  counter-­‐intuitively.	  One	  might	  hypothesize	  that	  if	  a	  person	  had	  been	  using	  for	  more	  time,	  their	  psychosocial	  habits	  and/or	  their	  brain	  chemistry	  would	  be	  more	  firmly	  set,	  thus	  creating	  a	  ‘steeper	  climb’	  out	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of	  the	  grip	  of	  addiction.	  However,	  the	  youngest	  patients,	  many	  of	  whom	  had	  only	  1-­‐2	  years	  of	  drug	  use	  actually	  fared	  the	  worst.	  The	  reasons	  for	  this	  are	  elusive—perhaps	  older	  patients	  (who	  averaged	  more	  years	  of	  drug	  use)	  have	  developed	  more	  personal	  maturity	  and	  motivation	  to	  stop	  using	  drugs.	  Another	  possible	  hypothesis	  is	  reflected	  in	  the	  language	  of	  ‘hitting	  rock	  bottom’	  that	  is	  used	  in	  addiction	  circles,	  describing	  the	  period	  at	  which	  a	  person	  experiences	  enough	  loss	  that	  they	  are	  ‘fed	  up’	  with	  using	  in	  a	  deep	  and	  profound	  sense.	  Perhaps	  younger	  patients	  who	  are	  new	  to	  opioid	  addiction	  have	  yet	  to	  experience	  this	  state,	  or	  fully	  appreciate	  the	  long-­‐term	  toll	  of	  addiction.	  	  Finally,	  the	  use	  of	  street	  buprenorphine	  has	  been	  uncovered	  as	  a	  positive	  prognostic	  indicator	  in	  a	  large	  recent	  study.14	  Our	  unadjusted	  results	  did	  show	  that	  individuals	  who	  had	  used	  street	  buprenorphine	  were	  unevenly	  distributed	  among	  the	  outcome	  groups.	  However,	  this	  characteristic	  failed	  to	  reach	  significance	  in	  the	  logistic	  models.	  It	  is	  possible	  that	  patients	  who	  have	  tried	  buprenorphine	  already	  are	  personally	  aware	  of	  the	  medication’s	  value.	  While	  some	  might	  find	  that	  they	  feel	  ‘high’	  when	  taking	  buprenorphine,	  evidence	  suggests	  that	  illicit	  use	  rarely	  results	  in	  euphoria,	  and	  instead	  serves	  to	  stave	  off	  the	  noxious	  symptoms	  of	  withdrawal,	  pain,	  or	  depression.28	  Unfortunately,	  this	  study	  sheds	  little	  light	  on	  the	  meaning	  of	  illicit	  buprenorphine	  use,	  and	  interesting	  questions	  remain	  about	  the	  actual	  impact	  of	  buprenorphine	  diversion	  on	  public	  health.	  	  	  
Limitations	  	  The	  most	  important	  limitation	  of	  this	  study	  is	  that	  it	  is	  retrospective	  and	  involves	  no	  control	  population	  or	  active	  intervention.	  Treatment	  protocols	  were	  not	  enforced,	  and	  variables	  could	  only	  be	  controlled	  mathematically.	  For	  that	  reason,	  it	  can	  be	  used	  only	  to	  determine	  correlations	  between	  variables.	  Importantly,	  while	  these	  correlations	  may	  theoretically	  have	  predictive	  value	  with	  respect	  to	  future	  patients,	  the	  model	  has	  not	  yet	  been	  validated	  in	  any	  other	  population,	  so	  results	  should	  be	  applied	  with	  caution.	  Also,	  the	  relationships	  between	  patient	  characteristics	  and	  outcomes	  cannot	  be	  considered	  causal,	  and	  for	  this	  reason,	  actively	  manipulating	  any	  specific	  characteristic	  of	  a	  particular	  patient	  (say,	  participation	  in	  drug	  counseling)	  may	  have	  no	  effect	  on	  that	  patient’s	  outcome,	  even	  if	  that	  characteristic	  was	  predictive	  in	  our	  model.	  Finally,	  the	  study	  is	  limited	  to	  one	  primary	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care	  practice,	  and	  care	  must	  be	  taken	  when	  trying	  to	  generalize	  these	  results	  to	  other	  practice	  types	  in	  other	  areas	  of	  the	  country.	  	  	  	   	  
Conclusions	  	  	   The	  population	  we	  studied	  reflects	  the	  changing	  demographics	  of	  opioid	  addiction,	  and	  exhibits	  high	  rates	  of	  concurrent	  non-­‐opioid	  drug	  use,	  mental	  illness,	  incarceration,	  homelessness,	  and	  hepatitis	  C.	  Our	  overall	  buprenorphine	  one-­‐year	  success	  rate	  of	  43.8%	  was	  on	  par	  with	  other	  studies	  in	  similar	  settings.	  However,	  we	  found	  that	  a	  given	  patient’s	  individual	  chances	  of	  success	  can	  vary	  greatly	  depending	  on	  certain	  characteristics.	  These	  trends	  are	  evident	  when	  single	  variables	  are	  investigated	  in	  isolation—for	  example,	  injection	  drug	  users,	  patients	  who	  are	  unemployed,	  are	  Hepatitis	  C	  positive,	  and	  who	  do	  not	  participate	  in	  drug	  counseling	  are	  less	  likely	  to	  succeed.	  However,	  the	  trends	  were	  amplified	  when	  we	  investigated	  overlapping	  traits	  in	  logistic	  regression	  models.	  The	  traits	  that	  are	  most	  associated	  with	  success	  at	  one	  year	  are	  female	  sex,	  increased	  age,	  employment,	  and	  hepatitis	  C	  negativity.	  Combinations	  of	  these	  four	  variables	  predict	  a	  wide	  ranging	  probability	  of	  success,	  from	  as	  low	  as	  10%	  chance	  of	  success	  for	  a	  20	  year	  old	  unemployed	  male	  with	  hepatitis	  C,	  to	  an	  80%	  chance	  for	  a	  50	  year	  old	  employed	  woman	  with	  no	  history	  of	  hepatitis	  C	  exposure.	  	  	   In	  secondary	  analyses,	  we	  also	  found	  that	  employment,	  female	  sex,	  and	  negative	  history	  of	  injection	  drug	  use	  all	  predict	  treatment	  retention	  past	  2	  months,	  such	  that	  a	  50	  year	  old	  woman	  with	  no	  history	  of	  injection	  drug	  use	  is	  3x	  more	  likely	  than	  a	  20	  year	  old	  male	  IV	  drug	  user	  to	  be	  retained	  in	  care.	  We	  also	  found	  that	  the	  percentage	  of	  early	  positive	  toxicology	  screens,	  and	  early	  failure	  to	  participate	  in	  counseling	  both	  predict	  treatment	  failure	  later	  in	  the	  course.	  Finally,	  we	  found	  that	  the	  use	  of	  non-­‐opioid	  drugs	  before	  treatment,	  use	  of	  cocaine	  during	  treatment,	  the	  presence	  of	  mental	  illness,	  history	  of	  overdose	  or	  incarceration,	  and	  prior	  treatment	  exposures	  all	  have	  no	  predictive	  power	  with	  respect	  to	  ultimate	  outcomes.	  	  While	  the	  study	  serves	  best	  to	  generate	  hypotheses	  for	  future	  studies,	  our	  results	  suggest	  a	  few	  clinical	  lessons.	  First,	  it	  appears	  centrally	  important	  to	  understand	  the	  individual	  risk	  profiles	  of	  patients	  who	  are	  candidates	  for	  buprenorphine	  therapy.	  Given	  our	  data,	  it	  seems	  very	  likely	  that	  different	  patients	  require	  different	  levels	  of	  observation	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and	  support	  in	  order	  to	  achieve	  the	  same	  chances	  of	  success.	  Physicians	  should	  be	  aware	  of	  each	  patient’s	  positive	  or	  negative	  prognostic	  indicators,	  and	  adjust	  their	  care	  accordingly.	  These	  risk	  factors	  include	  a	  ‘bumpy’	  start	  on	  buprenorphine,	  defined	  by	  numerous	  positive	  toxicology	  screens	  early	  in	  treatment,	  and	  failure	  to	  participate	  in	  supplemental	  addiction	  therapy.	  Lastly,	  we	  caution	  physicians	  who	  are	  tempted	  to	  discontinue	  therapy	  with	  buprenorphine	  based	  on	  patient	  use	  of	  non-­‐opioid	  drugs—cocaine	  in	  particular.	  	  Buprenorphine	  is	  a	  medication	  specifically	  designed	  to	  treat	  opioid	  addiction,	  and	  should	  not	  be	  expected	  to	  aid	  poly-­‐substance	  users	  in	  abstaining	  from	  non-­‐opioid	  drugs.	  Our	  data	  suggests	  that	  patients	  have	  the	  same	  ultimate	  chances	  of	  successfully	  attaining	  sobriety	  from	  opioids,	  whether	  or	  not	  they	  use	  non-­‐opioid	  drugs.	  Therefore,	  our	  data	  supports	  continuing	  cocaine-­‐using	  patients	  on	  buprenorphine	  while	  providing	  them	  with	  additional	  support	  to	  treat	  their	  other	  addictions.	  	  	  
Suggestions	  for	  future	  work	   	  
	   Much	  is	  yet	  to	  be	  learned	  about	  how	  best	  to	  use	  buprenorphine	  to	  tread	  addiction.	  	  One	  logical	  next	  step	  would	  be	  to	  validate	  the	  results	  of	  this	  study,	  and	  determine	  whether	  our	  models	  are	  actually	  predictive	  in	  other	  populations.	  The	  best	  way	  to	  do	  this	  would	  be	  using	  a	  prospective	  cohort	  study,	  in	  which	  patients	  are	  asked	  about	  the	  characteristics	  of	  interest	  before	  initiating	  therapy,	  and	  data	  are	  collected	  about	  how	  patents	  fare.	  The	  predictive	  algorithms	  generated	  here	  would	  be	  applied	  to	  this	  population,	  and	  tested	  for	  predictive	  strength.	  If	  our	  models	  were	  to	  evolve	  and	  become	  validated	  in	  multiple,	  larger	  populations,	  it	  would	  be	  possible	  to	  generate	  a	  simple	  tool	  that	  physicians	  could	  use	  to	  risk	  stratify	  their	  patients	  as	  they	  enter	  treatment.	  The	  tool	  could	  take	  the	  form	  of	  a	  ‘score,’	  which	  could	  be	  easily	  translated	  into	  an	  individualized	  probability	  of	  success	  or	  failure.	  Based	  on	  a	  patient’s	  score,	  a	  physician	  could	  alter	  the	  frequency	  of	  follow-­‐up	  or	  counseling	  visits,	  the	  dose/scheduling	  of	  buprenorphine,	  or	  spend	  more	  time	  focusing	  on	  cultivating	  a	  strong	  therapeutic	  relationship.	  In	  conclusion,	  we	  hope	  that	  these	  results	  will	  help	  support	  an	  approach	  to	  addiction	  care	  that	  is	  both	  more	  evidence-­‐based,	  and	  more	  personal	  at	  the	  same	  time.	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VII.	  Appendix	  	  Figure	  1	  Legend	  
X	  axis:	  Age;	  Y	  axis:	  Probability	  of	  falling	  into	  the	  ‘Success’	  group	  	  
Interpretation:	  The	  3-­‐letter	  sequences	  (ie.	  fNN,	  etc.)	  in	  the	  small	  box	  below	  the	  graph	  represent	  all	  possible	  combinations	  of	  the	  characteristics	  sex,	  employment	  status,	  and	  hepatitis	  C	  seropositivity	  respectively,	  such	  that	  f	  =	  Female,	  m	  =	  Male,	  Y	  =	  Yes,	  and	  N	  =	  No.	  Thus,	  ‘FNN’	  can	  be	  interpreted	  as	  ‘Female’	  ‘Not	  employed’	  and	  ‘Not	  hepatitis	  C	  positive.’	  ‘mYY’	  can	  be	  interpreted	  as	  ‘Male,’	  ‘Employed,’	  and	  ‘Hepatitis	  C	  positive.’	  Each	  combination	  of	  personal	  characteristics	  corresponds	  with	  a	  line	  on	  the	  graph	  as	  dictated	  by	  a	  unique	  color	  and	  pattern	  combination.	  Each	  line	  on	  the	  graph	  quantifies	  the	  predicted	  probability	  that	  a	  person	  will	  fall	  into	  the	  ‘success	  group,’	  given	  their	  age	  and	  any	  given	  combination	  of	  predictive	  characteristics.	  	  	  Figure	  2	  Legend	  	  
X	  axis:	  Age;	  Y	  axis:	  Probability	  of	  falling	  into	  the	  ‘Success’	  group	  	  
Interpretation:	  This	  graph	  can	  be	  read	  using	  the	  same	  general	  approach	  as	  in	  Figure	  1.	  In	  this	  case,	  all	  2-­‐letter	  sequences	  in	  the	  small	  box	  below	  the	  graph	  represent	  possible	  combinations	  of	  sex	  and	  employment,	  respectively,	  such	  that	  f	  =	  Female,	  m	  =	  Male,	  Y	  =	  Yes,	  and	  N	  =	  No.	  	  Thus,	  fN	  means	  ‘Female,	  Unemployed,’	  ‘fY’	  means	  ‘Female,	  Employed,’	  etc.	  As	  with	  Figure	  1,	  each	  2-­‐letter	  combination	  corresponds	  with	  a	  line	  on	  the	  graph,	  which	  represents	  the	  predicted	  probability	  that	  a	  person	  will	  fall	  into	  the	  ‘success	  group,’	  given	  their	  age	  and	  a	  given	  combination	  of	  predictive	  characteristics.	  	  	  Figure	  3	  Legend	  	  
X	  axis:	  %	  Positive	  Toxicology	  Screens	  in	  the	  first	  8	  weeks	  of	  Treatment;	  Y	  axis:	  Probability	  of	  falling	  into	  the	  ‘Success’	  group	  	  
Interpretation:	  This	  graph	  can	  be	  read	  using	  the	  same	  general	  approach	  as	  in	  Figures	  1	  and	  2.	  All	  2-­‐letter	  sequences	  in	  the	  small	  box	  below	  the	  graph	  represent	  possible	  combinations	  of	  drug	  counseling	  participation	  and	  injection	  drug	  use,	  in	  that	  order,	  such	  that	  NN	  means	  ‘No	  counseling,	  No	  injection	  drug	  use,’	  and	  NY	  means	  ‘No	  counseling,	  Yes	  injection	  drug	  use,’	  etc.	  As	  with	  Figures	  1	  and	  2,	  each	  2-­‐letter	  combination	  corresponds	  with	  a	  line	  on	  the	  graph,	  which	  represents	  the	  predicted	  probability	  that	  a	  person	  with	  that	  combination	  of	  characteristics	  at	  a	  given	  age	  will	  fall	  into	  the	  ‘success’	  group.	  	  
